Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thiogenesis TherapeuticsFRA:Q8M 20 PB Ratio is 4.88 as of Sep. 20, 2026. GuruFocus rates FRA:Q8M with a GF Score™ of 20/100. The stock has 1 warning sign investors should review. Among 1,223 Biotechnology companies, Thiogenesis Therapeutics ranks worse than 72.2% on this metric.
The historical rank and industry rank for Thiogenesis Therapeutics's PB Ratio or its related term are showing as below:
FRA:Q8M'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 5.31
Current: 5.31
During the past 7 years, Thiogenesis Therapeutics's highest PB Ratio was 5.31. The lowest was 0.00. And the median was 0.00.
FRA:Q8M's PB Ratio is ranked worse than 72.2% of 1223
companies
in the Biotechnology industry
Industry Median: 2.92
vs FRA:Q8M: 5.31
During the past 12 months, Thiogenesis Therapeutics's average Book Value Per Share Growth Rate was -85.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Thiogenesis Therapeutics was 191.10% per year. The lowest was 191.10% per year. And the median was 191.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Thiogenesis Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thiogenesis Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Thiogenesis Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Thiogenesis Therapeutics (FRA:Q8M) has a PB Ratio of 4.88 as of Sep. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Thiogenesis Therapeutics and its competitors. According to the industry distribution chart, Thiogenesis Therapeutics ranks #883 out of 1223 companies in the Biotechnology industry, placing it in the top 72.2%.
Is Thiogenesis Therapeutics' PB Ratio too high?
Thiogenesis Therapeutics' current PB Ratio is 4.88. The Biotechnology industry median PB Ratio is 2.92. Thiogenesis Therapeutics' value of 4.88 is 67.1% above this industry median. Based on the distribution chart, Thiogenesis Therapeutics ranks #883 out of 1223 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Thiogenesis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thiogenesis Therapeutics ranks #883 out of 1223 companies for PB Ratio. This places Thiogenesis Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.92. Thiogenesis Therapeutics' value of 4.88 is 67.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,223 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thiogenesis Therapeutics's current PB Ratio of 4.88 is 67.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Thiogenesis Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thiogenesis Therapeutics's current PB Ratio is 4.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (FRA:Q8M) has a current PB Ratio of 4.88. The current PB Ratio is 4.88 and 67.1% above the Biotechnology industry median of 2.92. Thiogenesis Therapeutics' overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Thiogenesis Therapeutics (FRA:Q8M), the current PB Ratio is 4.88 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
20GF Score
Get the complete analysis for FRA:Q8M
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q8M has been successfully added to your 
